Zhang Jian, Abdel-Rahman Abdel A
Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.
J Pharmacol Exp Ther. 2008 Jan;324(1):72-8. doi: 10.1124/jpet.107.129049. Epub 2007 Oct 16.
Imidazoline (I(1))-evoked hypotension is linked to enhanced phosphorylated extracellular signal-regulated kinase (pERK)1/2 production in the rostral ventrolateral medulla (RVLM). Recent cell culture findings suggest that nischarin is a candidate for the I(1) receptor. In the present study, nischarin antisense oligodeoxynucleotide (ODN) (AS1 or AS2), designed according to nischarin cDNA sequence, was administered intracisternally (i.c., 2 nmol/rat for 2 days) to knockdown central nischarin expression; control rats received the corresponding mismatched ODN (MM1 or MM2) or artificial cerebrospinal fluid (aCSF). We investigated the effects of AS1 or AS2 on nischarin expression in the RVLM, and on the hypotension and RVLM pERK1/2 production elicited by the I(1)-selective agonist rilmenidine (25 mug/rat i.c.). Compared with aCSF, the mismatched ODN (MM1 or MM2) had no significant effect on RVLM nischarin expression or the cardiovascular and cellular (RVLM pERK1/2) responses elicited by rilmenidine. However, either antisense ODN substantially (>80%) reduced nischarin expression in the RVLM (AS1/MM1, 3 +/- 1 versus 32 +/- 2 positive cells; AS2/MM2, 4 +/- 1 versus 31 +/- 2 positive cells) and abrogated rilmenidine (I(1))-evoked hypotension (AS1/MM1, -4.1 +/- 0.9 versus -10.8 +/- 1.9 mm Hg; AS2/MM2, -2.1 +/- 1.1 versus -15.3 +/- 2.5 mm Hg) and ERK1/2 activation in the RVLM (AS1/MM1, 10 +/- 1 versus 15 +/- 2 positive cells; AS2/MM2, 9 +/- 1 versus 18 +/- 2 positive cells). Finally, pERK1/2 generated by central I(1) receptor activation is colocalized with nischarin in the RVLM neurons. This is the first evidence in vivo that nischarin plays a critical role in I(1) receptor-mediated pERK1/2 production in the RVLM and the subsequent hypotension.
咪唑啉(I(1))诱发的低血压与延髓头端腹外侧区(RVLM)中磷酸化细胞外信号调节激酶(pERK)1/2生成增强有关。最近的细胞培养研究结果表明,尼斯查林是I(1)受体的一个候选分子。在本研究中,根据尼斯查林cDNA序列设计的尼斯查林反义寡脱氧核苷酸(ODN)(AS1或AS2)经脑池内注射(即,2 nmol/大鼠,共2天)以敲低中枢尼斯查林的表达;对照大鼠接受相应的错配ODN(MM1或MM2)或人工脑脊液(aCSF)。我们研究了AS1或AS2对RVLM中尼斯查林表达的影响,以及对I(1)选择性激动剂利美尼定(25 μg/大鼠,脑池内注射)诱发的低血压和RVLM中pERK1/2生成的影响。与aCSF相比,错配ODN(MM1或MM2)对RVLM中尼斯查林表达或利美尼定诱发的心血管和细胞(RVLM中pERK1/2)反应无显著影响。然而,两种反义ODN均显著(>80%)降低了RVLM中尼斯查林的表达(AS1/MM1,3±1对32±2个阳性细胞;AS2/MM2,4±1对31±2个阳性细胞),并消除了利美尼定(I(1))诱发的低血压(AS1/MM1,-4.1±0.9对-10.8±1.9 mmHg;AS2/MM2,-2.1±1.1对-15.3±2.5 mmHg)以及RVLM中ERK1/2的激活(AS1/MM1,10±1对15±2个阳性细胞;AS2/MM2,9±1对18±2个阳性细胞)。最后,中枢I(1)受体激活产生的pERK1/2与RVLM神经元中的尼斯查林共定位。这是体内首个证据,表明尼斯查林在RVLM中I(1)受体介导的pERK1/2生成及随后的低血压中起关键作用。